News

Analysis Group recently announced that it has established an office in Beijing, China. Analysis Group-Beijing will focus primarily on providing health care research and strategic consulting to the firm’s multinational pharmaceutical clients.
 
“When we open a new office, our objective is always to serve the needs of our clients, domestic and global. Our presence in Beijing will allow us to deepen our existing relationships with clients and important industry stakeholders and opinion leaders,” said Martha S. Samuelson, the president and CEO of Analysis Group.
 
The Beijing office will initially focus on health care consulting, particularly in economics, outcomes, epidemiology, pricing and market access, and strategy, explained Managing Principal Eric Qiong Wu, a health economist who has consulted to pharmaceutical and device companies, payers, and government agencies in North America, Europe, and Asia. “By 2013, China is expected to become the world’s third-largest pharmaceutical market. With a physical presence in China, our firm will be well-positioned to assist clients seeking to expand and enhance their own presences in China,” he said.
 
Analysis Group-Beijing will also work collaboratively with academic affiliate Dr. Gordon Liu, a professor of economics and the director of China Center for Health Economics Research at Peking University’s Guanghua School of Management. Dr. Liu is a leading expert on health and development economics, health policy reform, and pharmaceutical economics in China. He is recognized as a key figure in Chinese health care reform.

 Read related news item 

Read the press release